

PediatricsⁱⁿReview[®]

Atopic Dermatitis and Ichthyosis

Roselyn E. Epps

Pediatrics in Review 2010;31;278

DOI: 10.1542/pir.31-7-278

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pedsinreview.aappublications.org/content/31/7/278>

Pediatrics in Review is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1979. Pediatrics in Review is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2010 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0191-9601.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



Atopic Dermatitis and Ichthyosis

Roselyn E. Epps, MD*

Author Disclosure
Dr Epps has disclosed no financial relationships relevant to this article. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device.

Objectives After completing this article, readers should be able to:

1. Identify the characteristic features of atopic dermatitis and the factors that worsen it.
2. Understand that children who have atopic dermatitis are prone to recurrent infections, particularly with *Staphylococcus aureus* and herpes simplex virus.
3. Know the signs of Wiskott–Aldrich syndrome.
4. Plan the appropriate treatment of atopic dermatitis (emollients, corticosteroids, antibiotics, and allergen elimination when appropriate).
5. Recognize ichthyosis vulgaris and know that ichthyosis commonly occurs in children who have atopic dermatitis.
6. List the effective therapies in the management of ichthyosis vulgaris.
7. Distinguish between tinea pedis and atopic dermatitis.
8. Discuss the relationship of atopic dermatitis and food allergies and how to evaluate a patient who has both.
9. Explain why children who have one component of atopy syndrome (allergic rhinitis, asthma, atopic dermatitis) have a threefold greater risk of developing a second component.

Atopic Dermatitis

Atopic dermatitis (AD) is a chronic, relapsing dermatosis that features dry skin (xerosis), pruritus, and a personal or family history of eczema, allergic rhinitis or allergies, or asthma. Children who have one component of the atopic triad (AD, asthma, allergic rhinitis) are three times as likely to develop a second component. There is no sex predilection, and the onset frequently is in infancy. Although many affected children outgrow the condition by age 5 years, AD may persist into adolescence and adulthood. A smaller percentage of patients experience the onset of AD as older children or in adulthood.

The incidence and prevalence of AD have increased in the United States and worldwide, particularly in developed nations. Fewer than 10% of children were affected in the 1970s, but recent epidemiologic studies estimate that 15% to 20% of children are diagnosed with AD. The reason for the increased rate is unknown. The “hygiene hypothesis” proposes that decreased exposure to infectious and biologic antigens may result in an increased response to environmental antigens or perhaps to decreased immune suppression. Additional research must be conducted to determine the reasons for the increased prevalence and to address the trend.

Pathophysiology

Manifestations of AD are believed to be due to the interaction of certain genes, the environment, and immunologic response to the environment and specific trigger factors. Patients who have AD may be considered to have systemic changes, not just manifestations in the skin. Susceptible individuals can react to internal and environmental triggers in certain target organs, not only resulting in skin eruptions, but also in asthma and allergic rhinitis. Patients may exhibit extrinsic immunoglobulin E (IgE)-mediated sensitization due to external antigens, with allergenic signs and elevated allergen-specific IgE, or intrinsic sensitization, without IgE-mediated sensitization.

*Chief, Division of Dermatology, Children's National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, DC.

In acute AD lesions, T-helper 2 (TH2) cells are present in larger numbers than normal and have increased expression of specific cytokines that, in turn, stimulate B cells to produce IgE, resulting in peripheral eosinophilia. Cytokines and chemokines are released from cells in the skin, attracting other inflammatory cells and producing inflammatory mediators and reactions. Keratinocytes, Langerhans cells, endothelial cells, monocyte-macrophages, and eosinophils all play roles in the acute and chronic inflammation of AD.

Clinical Manifestations

Generally, the primary lesion is a red, rough, poorly defined dry papule or plaque. Scaling may be seen. There is no central clearing. In children of color or deep pigmentation, plaques can be papular or follicular, especially on the trunk or over the extensor areas of joints.

AD is diagnosed clinically and manifests particular patterns at different ages. Frequently, infants present with rough patches or plaques on the cheeks, the dorsa of the wrists, the ankles, and the lateral extremities. The perioral and diaper areas customarily are spared. After infancy, children develop flexural involvement, and the cheek areas improve. The neck, antecubital and popliteal fossae, and gluteal folds frequently are involved (Fig. 1).

Teenagers are more likely to experience eyelid eruptions. With age, the hands and feet also become more problematic, and AD may present as dyshidrotic eruptions. Any part of the body, from the scalp to the soles and including the lips and genitalia, may be affected at any age. Eruptions occur whether or not an offending factor or trigger is identified. Exacerbations and remissions are common and to be expected.

Secondary skin changes occur frequently. Oozing, weeping, and crust formation can develop, which may represent secondary infection. Hyperpigmentation as well as hypopigmentation and depigmentation (loss of pigmentation) can occur. Normal color of the skin usually returns when the signs and symptoms of AD resolve. Weeks to months may be required for the hyperpigmentation and hypopigmentation to resolve. If excoriations are deep or the inflammation is severe, scarring or depigmentation can be permanent.

Lichenification, a hallmark of AD, is thickening and accentuation of skin markings due to chronic scratching. Lichenified skin on the hands and feet is more likely to fissure. Excoriations are common, and some patients create erosions and deeper wounds by unrelenting, intense, repeated trauma. Repeated friction and trauma promote inflammation and trigger inflammatory reactions and pathways in affected skin. Lichenification also



Figure 1. Atopic dermatitis often involves the antecubital fossa. Lichenification and excoriations are evident in this example.

may occur in other dermatologic conditions that feature chronic scratching and pruritus.

Friction on the skin and scratching the skin are known to exacerbate pruritus and can initiate the “itch-scratch cycle,” in which the child scratches, itching in the involved area increases, the child continues to scratch, and the cycle continues. Plaques, papules, and nodules can result because of the escalating “itch-scratch cycle.”

Secondary Infection

Patients who have AD are more likely to develop skin and possibly systemic infections. One reason superinfection occurs more easily is due to altered skin barrier function, including apparent and imperceptible excoriations, fissures, and skin defects (Fig. 2). For patients who have AD, seemingly uninvolved skin is not normal. In addition to greater irritancy and dryness, there are immunologic differences in the type of TH2 cells and an increase in the number of TH2 cells within the skin. *Staphylococcus aureus* is an important cause of superinfection. *S. aureus* colonization by age 6 months, with frequent



Figure 2. Atopic dermatitis of this leg shows erythema, excoriations, and scaling consistent with superinfection.

colonization during the first year after birth, is associated with an increased prevalence and severity of AD. Impaired skin barrier function, a defective host immune response, and increased synthesis of extracellular matrix adhesion substances promote *S aureus* colonization.

Exotoxins secreted by *S aureus* penetrate the skin barrier and stimulate T cells and antigen-presenting cells, thereby exacerbating and contributing to persistent skin inflammation. *S aureus* overgrowth and superinfection can result in flares, impetigo, folliculitis, cellulitis, abscesses, bacteremia, and sepsis. Methicillin-resistant *S aureus*, now more common in the community, can be particularly problematic for patients who have AD and their families. The patient's infection must be treated, and treating the family may be necessary to minimize the risk of AD exacerbation in the patient. The clinician should consider culturing the atopic patient who is febrile, is unresponsive to therapy, or shows an inadequate response to maximized treatment that includes antibiotic therapy. Other bacteria also may be cultured from the AD patient's wounds and should be treated accordingly.

Although patients who have AD develop bacterial infections, they also may acquire viral and fungal infections. Eczema herpeticum occurs when AD is superinfected with a herpesvirus, either herpes simplex virus or varicella-zoster virus. Vesicles develop on affected and apparently unaffected skin and can be very painful. When disseminated, there may be associated viremia, fever, and lymphadenopathy, and patients can become very ill. Ocular involvement may occur innocuously when the patient rubs his or her eyes. Acyclovir should be administered intravenously in critical disseminated infections or orally for localized, recurrent infections in patients who

have AD. If herpesvirus infection involves the eye or periocular area, ophthalmology consultation is essential to manage herpes keratitis and to prevent permanent loss of vision.

Dermatophytes and yeast also can superinfect the skin. Patients who have AD can develop tinea capitis and tinea pedis, and it can be difficult at times to distinguish AD from tinea infection because both may involve pruritus, scaling, and inflammation. On physical examination, unlike AD, tinea pedis frequently develops in the toe web spaces (particularly the third and fourth). Tinea lesions frequently feature expanding plaques with central clearing and peripheral papules and scale. Potassium hydroxide slide examination of a sample taken from the skin from any affected body area, including the skin, the scalp, and hair, can help make the diagnosis.

Allergy and Environment

Allergic contact dermatitis can exacerbate AD. Common contact triggers include fragrances and preservatives in personal care products such as soaps, cleansers, shampoos, detergents, and certain emollients. Among other materials and substances that commonly elicit symptoms of allergic contact dermatitis are wool, nickel, synthetics, dyes, and rubber.

Physical and environmental factors also can play a role. Temperature changes between cold and hot environments (as when moving from an air conditioned enclosure to hot outdoor weather) or change of season can be problematic. Some children prefer warm or cool temperatures. Therefore, their dermatitis is milder in the summer or winter, respectively. Other environmental variables such as dust and mites, pollen, and ambient humidity can have an impact. Because sweating can produce pruritus and skin eruptions for some patients, treatment of AD may require modifying exercise regimens. Clothing tags, coarse fabrics, snug clothing, and footwear can worsen symptoms in a localized distribution. Emotional factors such as stress, anger, sleepiness, and boredom often increase pruritus.

The role of foods in causing AD can be significant for some children; food allergies can be present in up to 40% of patients who have AD. Symptoms include pruritus, urticaria, contact dermatitis, and exacerbation of AD as well as wheezing, asthma, and anaphylaxis. The symptoms can be immediate or delayed. Among the leading allergenic foods are milk and dairy products, eggs, wheat, soy, and peanuts. Some children outgrow allergies to particular foods, but peanuts and eggs are often the exception. Although some foods are difficult to avoid, the improved availability of nutritional information, di-

etary counseling, and food labeling helps families make proper dietary choices for children who have food allergies.

Allergy skin prick testing usually is more reliable after age 2 years; specific radioallergosorbent testing can be performed in infancy. The patient must not take oral antihistamines or steroid medications for several days before skin prick allergy testing; AD should be controlled as much as possible to allow proper evaluation while minimizing patient discomfort. Avoidance of allergenic substances identified by allergy testing occasionally benefits the patient who has AD, but AD can be exacerbated by unrelated factors while allergies are present. Allergy testing may be repeated and expanded if the patient does not improve after avoidance therapy.

Management

Treatment of AD requires a coordinated plan aimed at moisturizing dry skin, decreasing inflammation, treating any infections, and avoiding irritants and other factors associated with dermatitis flares. The regimen must be discussed with the family, patient, and clinicians to ensure compliance.

Bathing is an important aspect of general skin care for patients who have AD. Baths and showers should be brief and the water comfortably warm, never hot. After exposure to water, the skin should be patted or excess water brushed off of the skin before applying medication and moisturizer. Some patients improve and are maintained with daily or twice-daily bathing. Other patients experience drying and increased pruritus or discomfort with water contact, making infrequent bathing the required approach. In addition, during flares, some patients are unable to bathe or shower due to discomfort and pain. Bathing may be resumed when symptoms decrease.

Although not necessary, a variety of commercial products, including cleansers, soaps, oils, and oatmeal powders, can be combined with bath water. Fragrance-free soaps and cleansers are preferred, but which product benefits or is tolerated by each patient differs. The use of bubble bath, shampoo, and dishwasher detergent to cleanse the body should be avoided. For some, dilute chlorine bleach baths are beneficial, particularly for children whose AD improves after swimming in chlorinated pools. One-quarter to one-half cup of bleach in the bathtub (24 gallons or a standard tub filled 4 to 6 inches) should create a sufficient concentration without bleaching or damaging linens. Dilute white vinegar, extra light olive oil, and other products also have been used for bathing.

Because the skin of patients who have AD is dry, the

use of emollients is a cornerstone of therapy. Even without visible lesions, dry skin often is pruritic. Many products are available; no single emollient provides relief, moisturizes the skin, and improves skin barrier function for all patients. The medication vehicle (eg, cream versus ointment) and the presence of fragrance, preservatives, or other additives can affect the patient's response. Lotions, creams, ointments, and oils are composed of varying amounts of oil and water. Ointments are composed of more petroleum jelly, creams contain more water than oil, and lotions contain more water than cream. If the skin is excoriated or fissured, stinging or pain can occur from products containing more water. An optimal time for moisturizer application is immediately after the bath or shower. Many patients benefit from several emollient applications per day.

Topical corticosteroids have been a mainstay of AD therapy for approximately 50 years. Hydrocortisone (up to 1%) is available over the counter, and numerous prescription preparations are available (Table). Ointments, creams, lotions, gels, foams, and oil preparations are available. Different preparations deliver corticosteroid through the skin in varying potencies. If preparations are used sparingly and appropriately, adverse effects should be minimized. Adverse effects include skin atrophy, telangiectasias, striae, and systemic absorption. The use of potent and fluorinated corticosteroids on the face and intertriginous and diaper areas should be avoided due to increased absorption through thinner or occluded skin. Middle-strength to more potent corticosteroid medications may be required for treating lichenified areas or on the hands and feet due to the increased skin thickness and keratin of the skin layers.

Several clinical trials of topical corticosteroid use in the pediatric age group have been performed or are in progress; some topical corticosteroids are approved specifically for use in children and some infants. Many practitioners find topical corticosteroids useful to break the itch-scratch cycle, treat acute flares, and minimize symptoms of inflammation. When signs and symptoms improve, the frequency of topical corticosteroid application should be reduced while moisturizer use is continued. Continuous, prolonged application of topical corticosteroids also can produce tachyphylaxis or decreased effectiveness of the medication.

Oral corticosteroid therapy has limited use in treating AD. Although helpful for some severe flares, once therapy is discontinued, the rebound or subsequent flare that may occur might be more severe than the initial exacerbation and more difficult to control. Some patients become oral corticosteroid-dependent in their attempt to

Table. Topical Corticosteroids Ranked Strongest (Class I) to Weakest (Class VII)

	Medication	Available Formulation
Class I	Clobetasol propionate 0.05%	Cream, ointment, gel, foam
	Betamethasone dipropionate augmented 0.05%	Ointment
	Diflorasone diacetate 0.05%	Ointment
	Fluocinonide 0.01%	Ointment
	Halobetasol propionate 0.05%	Cream, ointment
Class II	Amcinonide 0.01%	Ointment
	Betamethasone dipropionate 0.05%	Ointment
	Betamethasone dipropionate augmented 0.05%	Cream
	Desoximetasone 0.25%	Cream, ointment
	Desoximetasone 0.05%	Gel
	Fluocinonide 0.05%	Cream, ointment, gel, solution
	Halcinonide 0.1%	Cream, ointment, solution
Class III	Mometasone furoate 0.1%	Ointment
	Amcinonide 0.1%	Cream, lotion
	Betamethasone valerate 0.1%	Ointment
	Desoximetasone 0.05%	Cream
	Fluocinonide emollient 0.05%	Cream
	Fluticasone propionate 0.005%	Ointment
	Halcinonide 0.1%	Solution
Class IV	Triamcinolone acetonide 0.1%	Ointment
	Betamethasone valerate 0.12%	Foam
	Fluocinonide acetonide 0.025%	Ointment
	Flurandrenolide 0.05%	Ointment
	Fluticasone propionate 0.05%	Cream
	Hydrocortisone valerate 0.2%	Ointment
	Mometasone furoate 0.1%	Cream, lotion
Class V	Triamcinolone acetonide 0.1%	Cream, ointment
	Betamethasone dipropionate 0.05%	Lotion
	Betamethasone valerate 0.1%	Cream
	Clocortolone pivalate 0.1%	Cream
	Desonide 0.05%	Ointment
	Fluocinolone acetonide 0.025%	Cream
	Flurandrenolide 0.05%	Cream
	Fluticasone propionate 0.01%	Oil
	Fluticasone propionate 0.05%	Cream
	Hydrocortisone butyrate 0.1%	Cream, ointment
	Hydrocortisone valerate 0.2%	Cream
Prednicarbate 0.1%	Cream	
Class VI	Triamcinolone acetonide 0.1%	Lotion
	Alclometasone 0.05%	Cream, ointment
	Betamethasone valerate 0.1%	Lotion
	Desonide 0.05%	Cream
	Fluocinolone acetonide 0.01%	Cream, lotion
	Hydrocortisone butyrate 0.1%	Solution
Class VII	Triamcinolone acetonide 0.1%	Cream
	Triamcinolone acetonide 0.025%	Cream, lotion
	Hydrocortisone acetonide, dexamethasone	Cream, ointment, lotion

Note: Vehicle affects medication potency for several products.

prevent flares and are more likely to develop adverse systemic effects such as hypothalamic-pituitary axis suppression, growth retardation, and cushingoid features.

Chronic, high-dose, or high-potency oral corticosteroid use has been shown to cause osteopenia or osteoporosis in children and adults. It is not known whether chronic intermittent topical corticosteroid use affects the bones of children. Some physicians give vitamin D and calcium supplementation to patients who have AD. Of note, the American Academy of Pediatrics has released new recommendations regarding vitamin D supplementation in children; the recommended minimum dose was doubled to 400 IU daily for infants and children. Clearly, corticosteroid use in children who have AD, the impact of therapy on bone health, and the role of vitamin D and calcium supplementation merit additional scientific study.

Topical calcineurin inhibitors are newer elements of the therapeutic armamentarium. Pimecrolimus 1% cream is approved for mild-to-moderate AD. Tacrolimus ointment is available in 0.03% and 0.1% strengths and is targeted for moderate-to-severe AD. Tacrolimus 0.03% and pimecrolimus are approved by the United States Food and Drug Administration for those ages 2 years and older; tacrolimus 0.1% is intended for those ages 15 years and older. Both medications can be used on any part of the body and are particularly beneficial for the eyelids, face, and intertriginous areas.

The most common adverse effects reported are burning at the site of application, headache, upper respiratory tract symptoms, cough, and pyrexia. In addition, exacerbation of viral infections, including herpesvirus infection, verrucae, and molluscum contagiosum, may be more likely in patients who use these products. A black box warning was placed on both medica-

tions, stating that long-term safety of topical calcineurin inhibitors has not been established and that these medications are not recommended for use in children younger than age 2 years. Additional therapeutic trials in children who have AD are planned and needed.

Several prescription topical nonsteroidal moisturizing creams have been approved for use in AD. Their purpose is to improve the hydrolipid layer and barrier function, relieve AD symptoms, and promote wound healing. They may be used alone or in combination with topical corticosteroids and calcineurin inhibitors. The nonsteroid creams Atopclair® Nonsteroidal Cream (Graceway Pharmaceuticals, Bristol, Tenn.), Eleton® Cream (Ferndale Laboratories, Ferndale, Mich.), Epiceram® Skin Barrier Emulsion (Promius Pharmaceuticals, Bridgewater, NJ), and MimyX® Cream (Steifel Pharmaceuticals, Bristol, Tenn.) are approved for all ages, for use on any area of the body, and may be used two to three times a day. Zetania® cream (Tiber Laboratories, Suwanee, Ga.) is approved for children 2 years of age and older. Patients allergic to any components of the creams should avoid their use.

Oral antihistamine drugs have been prescribed for patients who have AD. Although not statistically proven to be useful for treating pruritus generally, oral antihistamines can be helpful for children who have an urticarial component or decreased or altered sleep patterns due to pruritus.

Wiskott–Aldrich Syndrome

Wiskott–Aldrich syndrome is one important condition to consider in patients who have AD. This X-linked recessive disorder features eczematous eruptions in association with thrombocytopenia and recurrent infections. Thrombocytopenic purpura and hemorrhagic events may occur. The identified Wiskott–Aldrich syndrome protein (*WASP*) gene codes for a cytoplasmic protein that has multiple functions. The impaired humoral immune response to polysaccharide antigens seen in patients who have Wiskott–Aldrich syndrome makes patients susceptible to bacteria such as *Streptococcus pneumoniae* and *Pneumocystis jiroveci* and, later, to viruses. After the second decade of life, these patients are at risk for developing leukemia and lymphoma.

Job Syndrome

Another important condition to consider is Job syndrome, or hyperimmunoglobulin E syndrome (HIES), which is defined by eczematous eruptions associated with IgE concentrations greater than 2,000 IU/mL and repeated skin and sinopulmonary infections. The classic

autosomal dominant form is due to a mutation in the signal transducer and activator of the transcription 3 (*STAT3*) gene. Skin eruptions appear during the newborn period, with onset of infections during the first 3 postnatal months. Although the type of skin infection can vary, “cold” abscesses are typical and feature slight redness, no or low-grade fever, little systemic involvement, and minimal signs and symptoms, unlike abscesses seen in patients unaffected by HIES. Paronychia and candidal infections are common. Although the eczematous symptoms usually resolve, the recurrent pulmonary infections due to *S aureus* and *Haemophilus influenzae* progress to chronic lung infections and subsequent lung changes. Of note, children who have AD can have very high concentrations of IgE; conversely, patients who have HIES can have normal IgE concentrations.

Ichthyosis

Ichthyosis represents a group of disorders that involves abnormal epidermal skin barrier function, keratinization, and desquamation. Multiple types of ichthyosis have been described. Initially defined descriptively, the disorders now can be distinguished by genetic, histologic, biochemical, and molecular methods.

Ichthyosis vulgaris (IV) is the most common type, with an incidence of 1 in 250. The onset is during infancy or childhood, not at birth. Inheritance can be autosomal dominant or sporadic, so patients have a varied presentation. IV usually presents as fine white scales on the skin, sparing the antecubital and popliteal fossae. Scaling is most obvious on the lateral lower legs (Fig. 3). Hyperlinearity is noted on the palms and soles. IV can be innocuous and appear as an isolated finding. The histopathology may show a thinned-to-absent granular layer and a compact superficial stratum corneum. However, a skin biopsy may not be diagnostic; microscopically, IV can look like normal skin. IV often improves with age, and manifestations in adulthood may be minimal.

There are many forms of ichthyosis, most of which are rare. Ichthyosis can be inherited in autosomal or X-linked patterns or by spontaneous mutation. Although IV is rather common, X-linked ichthyosis, lamellar ichthyosis, and harlequin fetus are rare, well-described forms (Fig. 4). Several syndromes and related conditions of note include ichthyosis as part of the clinical picture. KID syndrome is defined as keratitis, ichthyosis, and deafness. Netherton syndrome, also called ichthyosis linearis circumflexa, features congenital erythroderma as well as atopic dermatitis, hair shaft abnormalities, and high IgE concentrations.



Figure 3. Ichthyosis vulgaris demonstrates fine, white scales.



Figure 4. Lamellar ichthyosis features larger, platelike scales.

Management

Treatment of IV usually involves the use of topical salicylic acid; lactic acid; or urea in lotion, cream, or ointment form. These products moisturize, soften the skin, and aid in desquamation. For patients who have both IV and AD, these products are more likely to cause irritation. The products should be used cautiously in children because total body application can result in systemic absorption and serious adverse effects. Salicylic acid, in particular, should be used in children after 1 year of age and then with caution due to risks of salicylate toxicity.

Research

Significant research has been performed in IV, AD, and related disorders. IV often coexists with AD, and research has shown a genetic basis for this association in certain populations. Gene mutations in keratin proteins alter skin barrier function. Most important, the *FLG* gene produces profilaggrin, and filaggrin is critical for AD expression. Multiple international and familial studies have shown that *FLG* mutations in patients who have AD alter normal skin formation, function, and hydration and result in severe AD, as well as asthma associated with AD.

The mutation for IV also has been identified. Studies have shown that Northern European patients who have IV have a statistically significant increased risk for developing AD as well. Also, patients who have both IV and AD have a statistically significant increased risk for developing asthma. Overall, there is strong evidence for a genetic and molecular basis for the association of IV and AD. More studies are in progress and are necessary for

Summary

- Based on strong research evidence and consensus, a multifaceted, individualized approach to treatment benefits patients who have atopic dermatitis and includes bathing, emollients, topical anti-inflammatory medications, allergen avoidance, and the use of antistaphylococcal antibiotics and antihistamines when clinically indicated. (1)(2)
- Based on strong research evidence, mutations in the *FLG* gene cause ichthyosis vulgaris, resulting in alterations in the skin protein filaggrin. (3)(4)
- Based on strong research evidence, atopic dermatitis is associated with certain populations who have ichthyosis vulgaris. (5)(6)(7)

elucidating the role of altered cutaneous barrier function in AD and IV.

References

1. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines." *J Am Acad Dermatol.* 2004;50:391–404
2. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. *J Clin Invest.* 2004;113:651–657
3. Smith FJ, Irvine AD, Terron-Kwiatkowski A, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. *Nat Genet.* 2006;38:337–342
4. Akiyama M, Shimizu H. An update on molecular aspects of the non-syndromic ichthyoses. *Exp Dermatol.* 2008;17:373–382
5. Hoffjan S, Stemmler S. On the role of the epidermal differentiation complex in ichthyosis vulgaris, atopic dermatitis and psoriasis. *Br J Dermatol.* 2007;157:441–449
6. Sandilands A, Terron-Kwiatkowski A, Hull PR, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. *Nat Genet.* 2007;39:650–654
7. Nomura T, Akiyama M, Sandilands A, et al. Specific filaggrin mutations cause ichthyosis vulgaris and are significantly associated with atopic dermatitis in Japan. *J Invest Dermatol.* 2008;128:1436–1441

Suggested Reading

- Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. *BMJ.* 2005;330:516
- Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. *Pediatrics.* 2008;122:812–824
- Lin YT, Yang CT, Chiang BL. Role of bacterial pathogens in atopic dermatitis. *Clin Rev Allergy Immunol.* 2007;33:167–177
- McGeady SJ. Immunocompetence and allergy. *Pediatrics.* 2004;113(4 suppl):1107–1113

PIR Quiz

Quiz also available online at <http://www.pedsinreview.aappublications.org>.

5. Infants who have atopic dermatitis often have clinical features that are different from those of older affected children. Which of the following areas of the body is *more* likely to be affected in infants?
 - A. Antecubital fossae.
 - B. Cheeks.
 - C. Eyelids.
 - D. Genitals.
 - E. Neck.

6. You are evaluating a 4-year-old boy who has a history of atopic dermatitis that usually affects his feet and popliteal fossae. He complains of itching and increased rash on his feet for several weeks. His mother feels that his atopic dermatitis is flaring up. Which of the following features makes a diagnosis of tinea pedis *more* likely than an exacerbation of atopic dermatitis?
 - A. Erythema.
 - B. Lesions in web spaces.
 - C. Plaques without central clearing.
 - D. Pruritus.
 - E. Scaling.

7. Which of the following treatments is recommended for all patients who have atopic dermatitis?
 - A. Complete avoidance of eggs and peanuts.
 - B. Daily prophylactic topical antibiotic cream.
 - C. Emollient application after a bath or shower.
 - D. Frequent bathing with hot water.
 - E. Periodic oral corticosteroid courses.

8. You are evaluating a 4-month-old boy during a health supervision visit. His mother complains that he is "always sick," and she is concerned about his constant "dry skin." She describes three upper respiratory tract infections and one episode of pneumonia that required hospitalization in the past 2 months. On physical examination, you note numerous scaly, erythematous patches on the infant's face and the extensor surfaces of his arms and legs. In addition, an erythematous diaper rash with satellite lesions is visible. You obtain a complete blood count, which reveals eosinophilia but no other abnormalities. Which of the following is the *most* likely diagnosis?
 - A. Allergic contact dermatitis.
 - B. Hyper-immunoglobulin E syndrome.
 - C. Lamellar ichthyosis.
 - D. Tinea corporis.
 - E. Wiskott-Aldrich syndrome.

Atopic Dermatitis and Ichthyosis

Roselyn E. Epps

Pediatrics in Review 2010;31;278

DOI: 10.1542/pir.31-7-278

Updated Information & Services

including high resolution figures, can be found at:
<http://pedsinreview.aappublications.org/content/31/7/278>

References

This article cites 11 articles, 2 of which you can access for free at:

<http://pedsinreview.aappublications.org/content/31/7/278#BIBL>

Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):

Dermatology

http://pedsinreview.aappublications.org/cgi/collection/dermatology_sub

Genetics

http://pedsinreview.aappublications.org/cgi/collection/genetics_sub

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:

</site/misc/Permissions.xhtml>

Reprints

Information about ordering reprints can be found online:

</site/misc/reprints.xhtml>

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

